HERO: Hemoglobin A1C Endocrine Response Optimization Platform

v0.1 of the HERO Platform

Scale of the Problem

Diabetes is a life threatening disease that has reached epidemic proportions in the US and elsewhere. The American Diabetes Association provides some statistics on the scope of the problem:

-In 2018, 34.2 million Americans, or 10.5% of the population, had diabetes.

-Nearly 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents

-The percentage of Americans age 65 and older [with diabetes] remains high, at 26.8%, or 14.3 million seniors.

-1.5 million Americans are diagnosed with diabetes every year.

-In 2015, 88 million Americans age 18 and older had prediabetes [roughly 42% of the 18+ population].

-Diabetes was the seventh leading cause of death in the United States in 2017. Diabetes was mentioned as a cause of death in a total of 270,702 certificates [in 2017].

American Diabetes Association

Financial Cost

While this problem is not only massive in scale, it is also a problem that exacts a heavy financial toll on both society and the individuals affected by the disease:

The total cost of diagnosed diabetes in the United States in 2017 was $327 billion.

American Diabetes Association

A person with type 1 diabetes incurred annual insulin costs of $5,705, on average, in 2016.

Reuters

The Solution: HERO

Built by leading experts in advanced analytics and machine learning, HERO (Hemoglobin A1C Endocrine Response Optimizer) is a cloud based advanced analytics platform designed to help Type 1 and Type 2 diabetics stabilize their blood glucose levels and ultimately put their diabetes into long term remission.

Field trials of this platform are presently under way.